Ask AI
Optimizing CLL SLL Care

CE / CME

Optimizing CLL/SLL Care: Expert Strategies for APPs to Integrate New Targeted Therapies and Practice-Changing Evidence

Nurse Practitioners/Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Released: September 30, 2025

Expiration: March 29, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

How confident do you feel in counseling patients with CLL to effectively engage them in their care with the goal of promoting adherence to their treatment plan?

2.

Allopurinol and hydration are important risk-mitigation strategies for which of the following therapies used in CLL management?

3.

Based on available evidence from head-to-head comparative phase III trials, which of the following pairs of BTK inhibitors would you tell a patient is associated with a similar risk for hypertension?

4.

Patient Case 2: A 68-Yr-Old Woman With CLL Harboring del(17p)



  • A 68-yr-old woman diagnosed with CLL harboring del(17p)

    • WBC 90 x 103 per microliter; Hb 85 g/dL; platelet counts 60 x 103 per microliter



  • Medical history:

    • Clinical depression receiving a serotonin antagonist; controlled headaches with medication; atrial-fibrillation receiving a direct oral anticoagulant



  • She receives triplet therapy with venetoclax + acalabrutinib + obinutuzumab

    • She initially experiences mild headaches on acalabrutinib that resolved with acetaminophen

    • Her best response to therapy was a partial remission, and MRD remained detectable throughout treatment



  • Within 18 months of starting therapy, she now presents with progressive lymphadenopathy, rising lymphocyte count, and new cytopenias consistent with disease progression 

Considering available information, which of the following is the best next-line of therapy for this patient?